Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. The company also develops ACCG-2671 and ACCG-3535, an oral small molecule amylin receptor agonist that is in phase1 clinical trial for the treatment of obesity; ANPA-0073, an oral small molecule APJ receptor agonist; and LTSE-2578, an antagonist that targets lysophosphatidic acid 1 receptor, a G-protein coupled receptors implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of idiopathic pulmonary fibrosis. In addition, it develops programs, including glucose-dependent insulinotropic polypeptide receptor (GIPR) program, which identified multiple GIPR agonist, dual GLP-1R/GIPR agonist, and GIPR antagonist hits for small molecule GIPR modulation that has the potential to provide a treatment in obesity; and GCG program, which identified multiple GCG receptor (GCGR) agonist and dual GLP-1R/GCGR agonist hits for small molecule GCGR modulation. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.…
Structure Therapeutics (GPCR) Posts Wider Losses, Is The Discount Too Deep?
Structure Therapeutics (NASDAQ: GPCR) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 281 employees.
The shares were at 16.13 USD on 20 November 2026, down 50.9% over 52 weeks. Its 52-week range is 16.08 USD to 94.90 USD, and it trades at the bottom of that range.
Its market capitalisation is 1.15B USD.
Structure Therapeutics reports return on equity of -9.3% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 1.23B USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. The next earnings report is expected on 25 February 2027.